MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease _ Pharmaceuticals, Biotechnology & Drugs
Symphogen
Attachments
Worldclinic
Parents
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
*Architects: BioPharmaceuticals_Inflammation, Allergy & Autoimmune
*Architects: Biotechnology _Monoclonal, Polyclonal, Bispecific Antibodies & Antibody-Drug Conjugates (ADC)s
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology
*Architects: Infectious Disease _ Pharmaceuticals, Biotechnology & Drugs
Industry: Denmark
Porfolio Companies: Novo Nordisk
Venture Capital: Series F
Children
A Clinical-stage Developer of Recombinant Polyclonal Antibodies for the Treatment of Cancer and Infectious and Autoimmune Diseases
Amount: ND* Round: Venture Capital Investor(s) PKA, Novo AS, Essex Woodlands Health Ventures
Symphogen is developing recombinant polyclonal antibodies (rpAb), a class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.
Symphogen, AS: Series F $135.4M (2011)